NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 53 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $19,501 | -22.0% | 38,312 | 0.0% | 0.01% | -12.5% |
| Q3 2022 | $25,000 | -35.9% | 38,312 | 0.0% | 0.01% | -46.7% |
| Q2 2022 | $39,000 | -45.8% | 38,312 | 0.0% | 0.02% | -37.5% |
| Q1 2022 | $72,000 | -61.1% | 38,312 | 0.0% | 0.02% | -57.1% |
| Q4 2021 | $185,000 | -33.2% | 38,312 | 0.0% | 0.06% | -36.4% |
| Q3 2021 | $277,000 | -21.8% | 38,312 | 0.0% | 0.09% | 0.0% |
| Q2 2021 | $354,000 | -25.0% | 38,312 | 0.0% | 0.09% | -8.3% |
| Q1 2021 | $472,000 | -12.6% | 38,312 | 0.0% | 0.10% | -13.5% |
| Q4 2020 | $540,000 | +17.4% | 38,312 | 0.0% | 0.11% | +22.0% |
| Q3 2020 | $460,000 | -27.7% | 38,312 | 0.0% | 0.09% | -51.1% |
| Q2 2020 | $636,000 | -36.7% | 38,312 | -56.6% | 0.19% | -44.6% |
| Q1 2020 | $1,004,000 | -7.6% | 88,185 | 0.0% | 0.34% | +29.7% |
| Q4 2019 | $1,086,000 | – | 88,185 | – | 0.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 2,291,133 | $1,166,187 | 1.01% |
| Privium Fund Management (UK) Ltd | 117,200 | $59,655 | 0.04% |
| Redmile Group, LLC | 1,850,566 | $941,938 | 0.04% |
| Baker Brothers Advisors | 3,821,740 | $1,945,266 | 0.01% |
| Kynam Capital Management, LP | 120,764 | $61,469 | 0.01% |
| Sio Capital Management, LLC | 38,312 | $19,501 | 0.01% |
| SIMON QUICK ADVISORS, LLC | 46,856 | $23,850 | 0.00% |
| Tri Locum Partners LP | 10,248 | $5,000 | 0.00% |
| Endurance Wealth Management, Inc. | 20,000 | $10 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 75,000 | $38,175 | 0.00% |